| Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors XS Wang, F Zhao, MJ Fisch, AM O'Mara, D Cella, TR Mendoza, ... Cancer 120 (3), 425-432, 2014 | 378 | 2014 |
| Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade J Zhou, KM Mahoney, A Giobbie-Hurder, F Zhao, S Lee, X Liao, S Rodig, ... Cancer immunology research 5 (6), 480-492, 2017 | 361 | 2017 |
| The symptom burden of cancer: evidence for a core set of cancer‐related and treatment‐related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice … CS Cleeland, F Zhao, VT Chang, JA Sloan, AM O'Mara, PB Gilman, ... Cancer 119 (24), 4333-4340, 2013 | 342 | 2013 |
| Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer JA Sparano, M Wang, F Zhao, V Stearns, S Martino, JA Ligibel, EA Perez, ... Cancer 118 (23), 5937-5946, 2012 | 277 | 2012 |
| Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma KT Flaherty, SJ Lee, F Zhao, LM Schuchter, L Flaherty, R Kefford, ... Journal of Clinical Oncology 31 (3), 373-379, 2013 | 269 | 2013 |
| Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer JA Sparano, F Zhao, S Martino, JA Ligibel, EA Perez, T Saphner, AC Wolff, ... Journal of Clinical Oncology 33 (21), 2353-60, 2015 | 265 | 2015 |
| Delivery settings and caesarean section rates in China S Guo, SS Padmadas, F Zhao, JJ Brown, RW Stones Bulletin of the World Health Organization 85 (10), 755-762, 2007 | 251* | 2007 |
| Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative … N Kornblum, F Zhao, J Manola, P Klein, B Ramaswamy, A Brufsky, ... Journal of Clinical Oncology 36 (16), 1556-1563, 2018 | 176 | 2018 |
| Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor–Positive Breast Cancer (E-3193 … AJ Tevaarwerk, M Wang, F Zhao, JH Fetting, D Cella, LI Wagner, ... Journal of Clinical Oncology 32 (35), 3948-58, 2014 | 167 | 2014 |
| Genome-wide association studies for taxane-induced peripheral neuropathy (TIPN) in ECOG-5103 and ECOG-1199 BP Schneider, L Li, M Radovich, C Miller, DA Flockhart, G Jiang, ... Clinical Cancer Research 21 (22), 5082-5091, 2015 | 153 | 2015 |
| Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (E2108) SA Khan, F Zhao, LJ Goldstein, D Cella, M Basik, M Golshan, TB Julian, ... Journal of Clinical Oncology 40 (9), 978-987, 2022 | 144 | 2022 |
| 1971年至2003年我国剖宫产率变化趋势及社会人口学影响因素的研究 郭素芳， 赵凤敏， 吴匡时， 崔颖， 吴久玲， 王临虹， 张彤， 李伯华 中华围产医学杂志 8 (3), 145-149, 2005 | 138 | 2005 |
| A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN … SA Khan, F Zhao, LJ Solin, LJ Goldstein, D Cella, M Basik, M Golshan, ... Journal of Clinical Oncology 38 (18_suppl), LBA2-LBA2, 2020 | 133 | 2020 |
| A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma (E1602) CL Slingluff, S Lee, F Zhao, KA Chianese-Bullock, WC Olson, ... Clinical Cancer Research 19 (15), 4228-4238, 2013 | 130 | 2013 |
| Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant … IA Mayer, F Zhao, CL Arteaga, WF Symmans, BH Park, BL Burnette, ... Journal of clinical oncology 39 (23), 2539-2551, 2021 | 125 | 2021 |
| Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide … DH Lawson, S Lee, F Zhao, AA Tarhini, KA Margolin, MS Ernstoff, ... Journal of Clinical Oncology 33 (34), 4066-4076, 2015 | 125 | 2015 |
| Race and hormone receptor–positive breast cancer outcomes in a randomized chemotherapy trial JA Sparano, M Wang, F Zhao, V Stearns, S Martino, JA Ligibel, EA Perez, ... Journal of the National Cancer Institute 104 (5), 406-414, 2012 | 112 | 2012 |
| Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer BP Schneider, F Zhao, M Wang, V Stearns, S Martino, V Jones, EA Perez, ... Journal of clinical oncology 30 (25), 3051-3057, 2012 | 109 | 2012 |
| Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern cooperative oncology group–American college of radiology imaging network … MK Garg, F Zhao, JA Sparano, J Palefsky, R Whittington, EP Mitchell, ... Journal of Clinical Oncology 35 (7), 718-726, 2017 | 93 | 2017 |
| E2112: randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor–positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research … RM Connolly, F Zhao, KD Miller, MJ Lee, RL Piekarz, KL Smith, ... Journal of Clinical Oncology 39 (28), 3171-3181, 2021 | 88 | 2021 |
Antonio C. Wolff, MD, FACP, FASCOProfessor of Oncology, Johns Hopkins UniversityAdresse e-mail validée de jhmi.edu